The inclusion of SARS-CoV-2 in the BIOFIRE® RP2.1 panel allows healthcare providers to quickly identify patients with common respiratory pathogens, as well as those with COVID-19, using one ...

The BIOFIRE Respiratory Panel 2.1 plus (RP2.1 plus) tests for 23 pathogens (19 viruses, including SARS-CoV-2, and 4 bacteria) responsible for the most frequent respiratory tract infections.

Rather than running multiple tests on samples, the PKamp Respiratory SARS-CoV-2 RT-PCR Panel is designed to conserve resources by testing a single nasopharyngeal, oropharyngeal or nasal swab sample ...

Key takeaways: The BD MAX Respiratory Viral Panel detected and differentiated between influenza A and B respiratory syncytial virus and SARS-CoV-2. The panel requires less than 1.5 minutes hands ...

The BD MAX Respiratory Viral Panel uses a single nasal or nasopharyngeal swab sample to determine if a patient has COVID-19, the flu or RSV. – BD Patients wondering whether they have COVID-19 ...

QIAGEN N.V. QGEN recently secured FDA clearance for the QIAstat-Dx Respiratory Panel Plus syndromic test. Previously authorized under the FDA Emergency Use Authorization (“EUA”) as the QIAstat ...

Importantly, based on viral load distribution in individuals that were tested for the first time in this study, approximately 20% of those infected with SARS-CoV-2 would be missed if sampled using ...

The new test is a combination of the company's original NxTAG RPP, an FDA-cleared in vitro diagnostic for syndromic respiratory infection testing, and the most relevant circulating pathogen today ...

The induction of CD4 type 2 helper T-cell (Th2) (interleukin-4, -5, or -13) responses has been associated with vaccine-associated enhanced respiratory disease (VAERD), as seen in some patients ...